BRIEF DESCRIPTION OF THE INSTITUTION
Uppsala University is one of the largest and oldest universities in Sweden with outstanding research infrastructure and world leading research in clinical medicine and epidemiology.
PREVIOUS EXPERIENCE RELEVANT TO THE TASKS
Johan Ärnlöv has during the last decade focused on biomarker research that provides further insights in to the detrimental interplay between the kidney and the cardiovascular system. He is currently leading a large project aiming at discovery of novel kidney damage biomarkers based on novel large scale omics-technologies.
DESCRIPTION OF ANY SIGNIFICANT INFRASTRUCTURE AND/OR MAJOR ITEMS OF TECHNICAL EQUIPMENT
The Uppsala Clinical Research center (UCR) began its operations in July 2001. UCR is an independent unit under the Disciplinary Domain of Medicine and Pharmacy, Uppsala University, and Uppsala University Hospital. It is located at Uppsala Science Park, which is close to the University Hospital. UCR works with projects directed by and in collaboration with clinical researchers at Uppsala University and at other universities and hospitals in Sweden and abroad. UCR has about 100 employees today, organized in these sections: clinical trials, quality registries, biometrics, laboratory/biobank (UCR Laboratory), and administration. UCR also has a group of researchers in various fields who are closely associated with the center. In clinical research/trials, the center of competence offers everything from consultation and support efforts in specific limited areas to complete solutions for major multicenter studies. In the field of registries, UCR has developed unique interactive Web-based technologies for continuous registration and reporting and offers specialist competence and comprehensive solutions for all types of databases and registries.
SHORT PROFILE OF KEY STAFF MEMBERS
Johan Ärnlöv: Johan Ärnlöv, Associate Professor of Cardiovascular Epidemiology at Uppsala University, has published more than 120 original articles, including several papers as a lead author in medical journals such as the New England Journal of Medicine, JAMA, Annals of Internal Medicine, Circulation, JACC, European Heart Journal and JASN. H-index 29. As a PI, he has received more than 3 000 000 Euros in grants during the last years.
LIST OF THE FIVE MOST RELEVANT PUBLICATIONS AND/OR PRODUCTS, SERVICES, OR OTHER ACHIEVEMENTS
- Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Ärnlöv J. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes. New England Journal of Medicine, 2008;358:2107-16,
- Ärnlöv J, Evans J, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease in non- hypertensive and non-diabetic individuals: The Framingham Heart Study. Circulation, 2005 Aug 16;112(7):969-75.
- Hagström E, Hellman P, Larsson T, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson M, Ärnlöv J. Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community, Circulation, 2009 Jun 2;119(21):2765-71.
- Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, Basu S, Larsson A, Lind L, Ärnlöv J. Serum cathepsin S and the risk for mortality. JAMA 2011 Sep 14;306(10):1113-21.
- Shlipak M, Matsushita K, Ärnlöv J, Inker L, Katz R, Polkinghorne K, Rothenbacher D, Sarnak M, Astor B, Coresh J, Levey A, Gansevoort RT. Cystatin C versus Creatinine in Determining Risk based on Kidney Function. The New England Journal of Medicine, 2013 Sep 5;369(10):932-43